| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/08/2006 | US20060121453 Pre-incubation assay methods |
| 06/08/2006 | US20060121447 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
| 06/08/2006 | US20060121180 Using electrochemical solution containing metal compound and bioactive materials; contacting substrate |
| 06/08/2006 | US20060121132 TNF-alpha production inhibitor comprising kavalactone as an active ingredient |
| 06/08/2006 | US20060121128 Increasing cytosolic calcium levels in airway epithelial cell by contacting purinergic (P2X) receptors on cell with zinc chloride; cystic fibrosis, asthma, allergies, polycystic kidney disease and salt-sensitive hypertension syndromes, diabetes; drug screening; nasal spray |
| 06/08/2006 | US20060121118 Antimycotic gel having high active compound release |
| 06/08/2006 | US20060121107 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 06/08/2006 | US20060121094 Preparation comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| 06/08/2006 | US20060121091 Cellular uptake of bioactive agents |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121072 Topical parasiticide formulations and methods of treatment |
| 06/08/2006 | US20060121059 Vaccine composition |
| 06/08/2006 | US20060121022 an antibody against protein C or activated protein C (aPC) comprising the heavy chain and light chain complementarity determining regions; used for suppressing activation of the blood coagulation system and antiinflammatory activity; therapy for diseases such as thrombosis and sepsis |
| 06/08/2006 | US20060121015 Probiotic bifidobacterium strains |
| 06/08/2006 | US20060120993 Treatment of lesions of the soft tissues |
| 06/08/2006 | US20060120977 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
| 06/08/2006 | DE20023815U1 Azithromycin enthaltende Zusammensetzungen Azithromycin-containing compositions |
| 06/08/2006 | DE19781792B4 6,7-Disubstituierte 8-Methyl-4-oxo-4H-1-benzopyran-5-carbonsäuren, Fermentationsverfahren zu deren Herstellung und diese Verbindungen enthaltende therapeutische Zusammensetzung 6,7-Disubstituted-8-methyl-4-oxo-4H-1-benzopyran-5-carboxylic acids, to their preparation and therapeutic composition containing compounds fermentation process |
| 06/08/2006 | DE102004028018A1 Verwendung von Stoffen, die Terpene und/oder Duftstoffalkohole freisetzen, zur Hemmung der Adhäsion von Mikroorganismen Use of substances which release terpenes and / or perfume alcohols to inhibit the adhesion of microorganisms |
| 06/08/2006 | DE102004023778A1 Verwendung von Wirkstoffkomplexen aus Pflanzen der Familie Zosteraceae Use of active compound complexes from plants of the family Zosteraceae |
| 06/08/2006 | CA2601629A1 Anti-hiv drug, polypeptide constituting the same, gene encoding the polypeptide and method of producing the anti-hiv drug |
| 06/08/2006 | CA2589833A1 Antimicrobial peptides with reduced hemolysis and methods of their use |
| 06/08/2006 | CA2588195A1 Novel antiviral and immune stimulant pharmaceutical composition |
| 06/08/2006 | CA2586501A1 Method for treating hiv infection through co-administration of tipranavir and gw695634 |
| 06/08/2006 | CA2586384A1 Method for treating hiv infection through co-administration of tipranavir and gw873140 |
| 06/08/2006 | CA2585663A1 Method for treating hiv infection through co-administration of tipranavir and sch-417690 |
| 06/08/2006 | CA2584365A1 Ascomycin crystalline forms and preparation thereof |
| 06/08/2006 | CA2581746A1 Staphylococcus aureus isd protein-based anti-infectives |
| 06/08/2006 | CA2580801A1 Naturally occuring igm antibodies that bind lymphocytes |
| 06/07/2006 | EP1666498A2 Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof |
| 06/07/2006 | EP1666480A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. |
| 06/07/2006 | EP1666477A1 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) q uinolonecarboxylic acid derivative |
| 06/07/2006 | EP1666466A2 Mutilin derivatives and their use as Antimicrobials |
| 06/07/2006 | EP1666454A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 06/07/2006 | EP1666453A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 06/07/2006 | EP1666092A2 Drug combination comprising a fatty acid and a uridine compound. |
| 06/07/2006 | EP1666060A1 Adjuvant systems and vaccines |
| 06/07/2006 | EP1666059A1 Novel vaccine containing adjuvant capable of inducing mucosal immunity |
| 06/07/2006 | EP1666058A2 Method of and compositions for immunization with the pseudomonas V antigen |
| 06/07/2006 | EP1666057A2 An acellular vaccine comprising Bordetella pertussis antigens |
| 06/07/2006 | EP1666055A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666035A1 Medicinal composition for treatment for fatty liver or liver disease |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1664270A1 Chimeric antigens for breaking host tolerance to foreign antigens |
| 06/07/2006 | EP1664124A2 Product comprising a c4bp core protein and a monomeric antigen, and its use |
| 06/07/2006 | EP1664118A1 Tlr2 antagonistic antibody and use thereof |
| 06/07/2006 | EP1664096A1 Antimicrobial polypeptides |
| 06/07/2006 | EP1664091A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 06/07/2006 | EP1664072A1 Novel sulfenamides |
| 06/07/2006 | EP1664071A1 Novel sulfenamide oxides |
| 06/07/2006 | EP1664064A2 Oxazaborolidines as bacteria effectors |
| 06/07/2006 | EP1664059A1 Thienopyrroles as antiviral agents |
| 06/07/2006 | EP1664052A1 Fused heterocycles as inhibitors of glutamate racemase (muri) |
| 06/07/2006 | EP1664046A1 Aza-quinolinol phosphonate integrase inhibitor compounds |
| 06/07/2006 | EP1664040A1 Gyrase inhibitors |
| 06/07/2006 | EP1664025A1 Pyrrol derivatives with antibacterial activity |
| 06/07/2006 | EP1664000A1 Isoxazoles as peptide deformylase inhibitors |
| 06/07/2006 | EP1663977A2 2-pyridinone derivatives, having hiv inhibiting properties |
| 06/07/2006 | EP1663315A2 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 06/07/2006 | EP1663289A2 Methods for treating or ameliorating ghrelin-associated diseases and disorders |
| 06/07/2006 | EP1663287A1 Use of modified cyclosporins for the treatment of hcv disorders |
| 06/07/2006 | EP1663271A1 Use of gentiana lutea extracts as an antimicrobial agent |
| 06/07/2006 | EP1663265A1 Bacteriophage-containing therapeutic agents |
| 06/07/2006 | EP1663258A2 Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans |
| 06/07/2006 | EP1663244A2 Pteridine derivatives for the treatment of septic shock and tnf-alpha-related diseases. |
| 06/07/2006 | EP1663240A1 Combinations of a pyrimidine containing nnrti with rt inhibitors |
| 06/07/2006 | EP1663233A1 Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| 06/07/2006 | EP1663225A1 Compositions for veterinary and medical applications |
| 06/07/2006 | EP1663220A1 Novel process, salts, compositions and use |
| 06/07/2006 | EP1663198A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) |
| 06/07/2006 | EP1663187A2 Antiflatulents in combination with histamine h1-receptor antagonists for treating gastrointestinal disorders |
| 06/07/2006 | EP1663181A2 Protein binding compounds |
| 06/07/2006 | EP1663146A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 06/07/2006 | EP1663124A1 Antimicrobial compositions and methods of use |
| 06/07/2006 | EP1663107A2 Rifamycin analogs and uses thereof |
| 06/07/2006 | EP1492789B1 Tropane derivatives as ccr5 modulators |
| 06/07/2006 | EP1476467B1 Immunoglobulin igg3 as a marker for protecting against infectious viral diseases, and the uses of the same |
| 06/07/2006 | EP1446106A4 Optimal polymer mixtures for gastric retentive tablets |
| 06/07/2006 | EP1425029A4 Peptidomimetics of biologically active metallopeptides |
| 06/07/2006 | EP1421075B1 Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv |
| 06/07/2006 | EP1409673B1 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 06/07/2006 | EP1406878B1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 06/07/2006 | EP1364023B1 Gene highly expressed in cartilage tissues |
| 06/07/2006 | EP1296673A4 Antimicrobial coatings |
| 06/07/2006 | EP1265630B1 Use of insulin for the treatment of cartilagenous disorders |
| 06/07/2006 | EP1254234B1 Haemophilus influenza outer membrane protein and use thereof in vaccination |
| 06/07/2006 | EP1140965B1 Antibacterial protonated oligonucleotides |
| 06/07/2006 | EP1124592B1 Textured and porous silicone rubber |
| 06/07/2006 | EP1095059B1 Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
| 06/07/2006 | EP1002081B1 Delayed progression to aids by a missense allele of the ccr2 gene |
| 06/07/2006 | EP0871735B1 Therapeutic compositions for the treatment of Lawsonia intracellularis infections |
| 06/07/2006 | EP0813538B1 Compositions and methods for the treatment and diagnosis of immune disorders |
| 06/07/2006 | EP0772437B1 Compositions for delivery of genetic material |
| 06/07/2006 | CN1784493A Modified beta-lactamases and uses thereof |
| 06/07/2006 | CN1784422A Severe acute respiratory syndrome (SARS) causing coronavirus |
| 06/07/2006 | CN1784390A Substituted dihydrochinazolines having antiviral properties |
| 06/07/2006 | CN1784231A 1-amino 1H-imidazoquinolines |
| 06/07/2006 | CN1782071A Recombinant mva virus and the use thereof |
| 06/07/2006 | CN1781947A Modified peptides as therapeutic agents |